In Apr26, Axsome has entered into an asset purchase agreement with Takeda for TAK-063 (balipodect), with an intention to develop it for treating schizophrenia & Tourette syndrome (P-III study-enabling activities for schizophrenia to begin in 2026) Total Revenue: $29.44B Founded Year: 1987 Total Employees: 17,000 Headquarters: California, United States Market Cap: $176.37B Stock Exchange: NASDAQ Gilead is a global biopharma company focused on antivirals and specialty therapeutics, with leadership in HIV, oncology, and liver diseases anchored by a strong antiviral franchise and an expanding oncology portfolio
Food and Drug Administration (FDA) approved Keytruda (Pembrolizumab), a PD-1 monoclonal antibody for the treatment of cancer
Many of the cardiovascular, renal, and hepatic benefits of semaglutide, sold as Ozempic and Wegovy, appear to occur independently of weight loss or glucose improvement, he notes
Each GLP-1 medication has patient-specific dosing
In 2015, the FDA approved Darzalex for the treatment of multiple myeloma (MM), making it the first CD38 antibody approved globally for MM treatment
In contrast, Bydureon is a long-acting, once-weekly formulation, developed using a microsphere-based delivery system
